Halozyme Therapeutics Dirección

Dirección controles de criterios 2/4

El CEO de Halozyme Therapeutics es Helen Torley , nombrado en Jan 2014, tiene una permanencia de 10.83 años. compensación anual total es $11.82M, compuesta por 7.8% salario y 92.2% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.53% de las acciones de la empresa, por valor de $32.80M. La antigüedad media del equipo directivo y de la junta directiva es de 2.8 años y 10.8 años, respectivamente.

Información clave

Helen Torley

Chief Executive Officer (CEO)

US$11.8m

Compensación total

Porcentaje del salario del CEO	7.8%
Permanencia del CEO	10.8yrs
Participación del CEO	0.5%
Permanencia media de la dirección	2.8yrs
Promedio de permanencia en la Junta Directiva	10.8yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Helen Torley en comparación con los beneficios de Halozyme Therapeutics?
Fecha	Compensación total	Salario	Ingresos de la empresa
Sep 30 2024	n/a	n/a	US$392m
Jun 30 2024	n/a	n/a	US$337m
Mar 31 2024	n/a	n/a	US$319m
Dec 31 2023	US$12m	US$920k	US$282m
Sep 30 2023	n/a	n/a	US$254m
Jun 30 2023	n/a	n/a	US$234m
Mar 31 2023	n/a	n/a	US$182m
Dec 31 2022	US$10m	US$872k	US$202m
Sep 30 2022	n/a	n/a	US$211m
Jun 30 2022	n/a	n/a	US$366m
Mar 31 2022	n/a	n/a	US$435m
Dec 31 2021	US$7m	US$830k	US$403m
Sep 30 2021	n/a	n/a	US$409m
Jun 30 2021	n/a	n/a	US$229m
Mar 31 2021	n/a	n/a	US$163m
Dec 31 2020	US$7m	US$791k	US$129m
Sep 30 2020	n/a	n/a	US$22m
Jun 30 2020	n/a	n/a	-US$40m
Mar 31 2020	n/a	n/a	-US$80m
Dec 31 2019	US$6m	US$761k	-US$72m
Sep 30 2019	n/a	n/a	-US$40m
Jun 30 2019	n/a	n/a	-US$43m
Mar 31 2019	n/a	n/a	-US$51m
Dec 31 2018	US$6m	US$725k	-US$80m
Sep 30 2018	n/a	n/a	US$46m
Jun 30 2018	n/a	n/a	US$76m
Mar 31 2018	n/a	n/a	US$68m
Dec 31 2017	US$5m	US$671k	US$63m

Compensación vs. Mercado: La compensación total de Helen($USD11.82M) está por encima de la media de empresas de tamaño similar en el mercado UK ($USD3.27M).

Compensación vs. Ingresos: La compensación de Helen ha aumentado más de un 20% en el último año.

CEO

Helen Torley (61 yo)

10.8yrs

Permanencia

US$11,820,858

Compensación

Dr. Helen I. Torley, M.B. Ch. B., M.R.C.P. has been Chief Executive Officer and President of Halozyme Therapeutics, Inc. since January 6, 2014. He serves as President, CEO & Director at Halozyme, Inc. Prio...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Helen Torley	President	10.8yrs	US$11.82m	0.53% $ 32.8m
Nicole LaBrosse	Senior VP & CFO	2.8yrs	US$3.85m	0.012% $ 750.5k
Michael LaBarre	Senior VP & CTO	no data	US$3.24m	0.14% $ 8.4m
Mark Snyder	Senior VP & Chief Legal Officer	2.8yrs	US$3.61m	0.0092% $ 566.1k
Cortney Caudill	Chief Operations Officer	1.1yrs	sin datos	sin datos
Tram Bui	Head of Investor Relations & Corporate Communications	2.8yrs	sin datos	sin datos
Amy Fox	Chief Human Resources Officer	4.8yrs	sin datos	sin datos
Gary Grote	Chief Commercial Officer	1.5yrs	sin datos	sin datos
Christopher Wahl	Chief Business Officer	1.3yrs	sin datos	sin datos
Charles Theuer	Chief Medical Officer	less than a year	sin datos	sin datos

2.8yrs

Permanencia media

60yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 0J2O se considera experimentado (2.8 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Helen Torley	President	10.8yrs	US$11.82m	0.53% $ 32.8m
Connie Matsui	Independent Director	18.3yrs	US$460.02k	0.15% $ 9.1m
Jeffrey Henderson	Independent Chair of the Board	9.3yrs	US$555.02k	0.037% $ 2.3m
Daniel Von Hoff	Member of the Scientific Advisory Board	20.3yrs	sin datos	sin datos
Barbara Duncan	Independent Director	1.8yrs	US$528.15k	sin datos
Jeffrey Bleil	Member of the Advisory Board	no data	sin datos	sin datos
Gregory Frost	Chairman of Scientific Advisory Board	10.8yrs	US$68.17k	sin datos
Gerhard Baumgartner	Member of Scientific Advisory Board	20.4yrs	sin datos	sin datos
Sue Bailey	Member of Scientific Advisory Board	19.3yrs	sin datos	sin datos
Matthew Posard	Independent Director	11.7yrs	US$471.83k	0.039% $ 2.4m
Akiko Miyashita	Independent Director	2.7yrs	US$455.02k	0.011% $ 691.9k
Bernadette Connaughton	Independent Director	6.2yrs	US$470.02k	0.032% $ 2.0m

10.8yrs

Permanencia media

66yo

Promedio de edad

Junta con experiencia: Los miembros de la junta directiva de 0J2O son experimentados ( 10.8 años antigüedad media).

Halozyme Therapeutics Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Independent Director recently sold US$1.7m worth of stock

Independent Director recently sold US$1.0m worth of stock

Halozyme Therapeutics, Inc. Announces the Election of Mahesh Krishnan, M.D. to its Board of Directors

Halozyme Therapeutics, Inc., Annual General Meeting, Apr 25, 2024

Independent Director recently sold US$875k worth of stock

Insufficient new directors

Recent updates

Investor sentiment deteriorates as stock falls 20%

New minor risk - Share price stability

Halozyme Reportedly Interested in Acquiring Evotec for $2.1 Billion

Investor sentiment improves as stock rises 18%

Third quarter 2024 earnings released: EPS: US$1.08 (vs US$0.62 in 3Q 2023)

Halozyme Therapeutics, Inc. Revises Earnings Guidance for the Year 2024

Halozyme Therapeutics, Inc. to Report Q3, 2024 Results on Oct 31, 2024

Investor sentiment deteriorates as stock falls 18%

Halozyme Therapeutics, Inc. Announces FDA Approval of Roche's Subcutaneous OCREVUS ZUNOVO with ENHANZE for People with Relapsing and Primary Progressive Multiple Sclerosis

Halozyme Therapeutics, Inc. Announces FDA Approval of Roche's Tecentriq Hybreza™ With ENHANZE® for Multiple Types of Cancer

Independent Director recently sold US$1.7m worth of stock

Second quarter 2024 earnings released: EPS: US$0.73 (vs US$0.57 in 2Q 2023)

Halozyme Therapeutics, Inc. Reiterates Financial Guidance for 2024

Halozyme Therapeutics, Inc. to Report Q2, 2024 Results on Aug 06, 2024

Halozyme Therapeutics, Inc. Announces Roche's OCREVUS SC with ENHANZE Receives European Commission Approval for Relapsing and Primary Progressive Multiple Sclerosis

Halozyme Therapeutics, Inc. Announces argenx Receives FDA Approval for VYVGART Hytrulo Co-Formulated with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy

Independent Director recently sold US$1.0m worth of stock

Halozyme Therapeutics, Inc. Updates Earnings Guidance for the Full Year 2024

Investor sentiment improves as stock rises 19%

First quarter 2024 earnings released: EPS: US$0.60 (vs US$0.29 in 1Q 2023)

Halozyme Therapeutics, Inc. Reiterates Revenue Guidance for 2024

Halozyme Therapeutics, Inc. Announces the Election of Mahesh Krishnan, M.D. to its Board of Directors

Halozyme Therapeutics, Inc. to Report Q1, 2024 Results on May 07, 2024

Halozyme Therapeutics, Inc., Annual General Meeting, Apr 25, 2024

Full year 2023 earnings released: EPS: US$2.13 (vs US$1.48 in FY 2022)

Halozyme Therapeutics, Inc. Provides Earnings Guidance for the Year 2024

Halozyme Therapeutics, Inc. to Report Q4, 2023 Results on Feb 20, 2024

Halozyme Announces Argenx Receives Approval in Japan for Vyvdura®? Co-Formulated with Enhanze®? for Generalized Myasthenia Gravis

Halozyme Therapeutics, Inc. Provides Earnings Guidance for the Twelve Months Ended December 31, 2023

Halozyme Announces Takeda Receives FDA Approval for Hyqvia® Co-Formulated with Enhanze® as Maintenance Therapy in Adults with Chronic Inflammatory Demyelinating Polyneuropathy

Halozyme Announces Roche Receives European Commission Approval of Tecentriq®? SC with ENHANZE®? Representing the EU's First Subcutaneous PD(L)1 Cancer Immunotherapy for Multiple Cancer Types

Third quarter 2023 earnings released: EPS: US$0.62 (vs US$0.45 in 3Q 2022)

Halozyme Therapeutics, Inc. to Report Q3, 2023 Results on Nov 06, 2023

Halozyme Therapeutics, Inc. Reports Positive Topline Results from the Phase 3 Checkmate-67T Trial Evaluating Subcutaneous (SC) Formulation of Opdivo (Nivolumab) with Enhanze

Halozyme Announces Positive Clinical Data of its High-Volume Auto-Injector Demonstrating Successful Rapid Subcutaneous Drug Delivery

Halozyme Therapeutics, Inc Announces Approval of Roche's Tecentriq® Subcutaneous (SC) with ENHANZE® in Great Britain

Independent Director recently sold US$875k worth of stock

Second quarter 2023 earnings released: EPS: US$0.57 (vs US$0.16 in 2Q 2022)

Halozyme Therapeutics, Inc. Revises Earnings Guidance for the Full Year 2023

Halozyme Therapeutics, Inc. to Report Q2, 2023 Results on Aug 08, 2023

Positive Topline Data Reported from argenx's ADHERE Study of VYVGART® Hytrulo with Halozyme's ENHANZE® Drug Delivery Technology in Patients with Chronic Inflammatory Demyelinating Polyneuropathy

Positive Results Announces from Phase 3 OCARINA II Trial Evaluating Roche's OCREVUS® (ocrelizumab) with Halozyme's ENHANZE® Drug Delivery Technology in Patients with Multiple Sclerosis

Halozyme Announces argenx Receives FDA Approval for VYVGART Hytrulo With ENHANZE for Subcutaneous Use in Generalized Myasthenia Gravis

Insufficient new directors

First quarter 2023 earnings released: EPS: US$0.29 (vs US$0.44 in 1Q 2022)

Halozyme Therapeutics, Inc. Reiterates Revenue Guidance for the Full Year 2023

Insufficient new directors

Investor sentiment deteriorates as stock falls 19%

Independent Director recently sold US$962k worth of stock

Full year 2022 earnings released: EPS: US$1.48 (vs US$2.86 in FY 2021)

Halozyme Therapeutics, Inc. to Report Q4, 2022 Results on Feb 21, 2023

Halozyme Therapeutics Appoints Barbara Duncan to Its Board of Directors

Halozyme Therapeutics, Inc. Provides Revenue Guidance for the Fiscal Year 2023

Independent Director recently sold US$1.7m worth of stock

CFO & Director recently sold US$269k worth of stock

Third quarter 2022 earnings released: EPS: US$0.45 (vs US$1.53 in 3Q 2021)

Halozyme Therapeutics, Inc. Reiterates Financial Guidance for the Year 2022

Halozyme Therapeutics, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Second quarter 2022 earnings released: EPS: US$0.16 (vs US$0.64 in 2Q 2021)

Halozyme Therapeutics, Inc. Revises Earnings Guidance for the Year 2022

Halozyme Therapeutics, Inc. Announces Positive Results from Phase III IMscin001 Study Evaluating Subcutaneous Formulation of Tecentriq with ENHANZE in Advanced Non-Small Cell Lung Cancer

Halozyme Therapeutics, Inc. to Report Q2, 2022 Results on Aug 09, 2022

Investor sentiment improved over the past week

Halozyme Therapeutics, Inc. Announces Commercial Launch of TLANDO, an Oral Treatment for Testosterone Replacement Therapy

Investor sentiment improved over the past week

Halozyme Therapeutics, Inc. (NasdaqGS:HALO) completed the acquisition of Antares Pharma, Inc. (NasdaqCM:ATRS).

Halozyme Therapeutics, Inc. Reiterates Earnings Guidance for the Year 2022

First quarter 2022 earnings released: EPS: US$0.44 (vs US$0.20 in 1Q 2021)

Halozyme Therapeutics, Inc. to Report Q1, 2022 Results on May 10, 2022